Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/21360Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tsabouri, S. | en |
| dc.contributor.author | Georgiou, I. | en |
| dc.contributor.author | Katsaraki, A. | en |
| dc.contributor.author | Bourantas, K. L. | en |
| dc.date.accessioned | 2015-11-24T19:14:39Z | - |
| dc.date.available | 2015-11-24T19:14:39Z | - |
| dc.identifier.issn | 1466-4860 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21360 | - |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Aged, 80 and over | en |
| dc.subject | Disease Progression | en |
| dc.subject | Female | en |
| dc.subject | Gene Deletion | en |
| dc.subject | Gene Frequency | en |
| dc.subject | Genetic Predisposition to Disease | en |
| dc.subject | Genotype | en |
| dc.subject | Glutathione Transferase/*genetics | en |
| dc.subject | Greece | en |
| dc.subject | Homozygote | en |
| dc.subject | Humans | en |
| dc.subject | Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/*genetics | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Odds Ratio | en |
| dc.subject | Risk Factors | en |
| dc.title | Glutathione sulfur transferase M1 and T1 genotypes in chronic lymphoblastic leukemia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1038/sj.thj.6200555 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/15570292 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2004 | - |
| heal.abstract | Glutathione sulfur transferases (GSTs) is a group of enzymes involved in the detoxification process of carcinogens and other substances. The genes encoding isoenzymes M1 and T1 are polymorphic in humans and the phenotypic absence of enzyme activity (null genotype) may have an effect on the risk of chronic lymphoblastic leukemia (CLL). Our purpose was to examine whether the GSTM1 and GSTT1 homozygous null genotypes altered the risk of CLL. DNA was extracted from the peripheral blood of 27 patients with CLL and 147 cancer-free controls; both groups originated from a defined population (residents of the Ioannina region, northwestern Greece) and were similar with regard to mean age, race and sex; GSTM1 and GSTT1 were simultaneously analyzed by a multiplex polymerase chain reaction (PCR) method and Fisher's exact test was used for comparisons between the two groups. A significantly increased incidence of the GSTM1 null genotype was found in the group of patients compared to the controls (74.07 versus 34.69%, P = 0.0002). Additionally, the incidence of the GSTT1 null genotype was comparable in patients and controls (25.92 versus 10.20%, P = 0.05). The frequency of the combined GSTM1 null/T1 null genotype was significantly different between patients and controls (14.81 versus 2.04%, P = 0.012). However, there was no relationship between the advanced stage of the disease and the GSTs status. Individuals with the GSTM1 and GSTT1 null genotypes may have enhanced susceptibility to CLL. | en |
| heal.journalName | Hematol J | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
